DNA earnings date and last-quarter result: last quarter miss, P/E -1.46. Updated 2026-07-23.
Ginkgo Bioworks Holdings (DNA) Research Hub
Ginkgo Bioworks Holdings (DNA) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 10.02 USD (+0.30%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.46, market cap 0.52B. This hub links to the full technical, earnings and options research available for DNA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 10.02 USD (+0.30%) |
| 52-week range | 6.52 USD – 18.22 USD |
| Trend regime | Range |
| 14-day RSI | 33.1 (Bearish) |
| Trailing P/E | -1.46 |
| Market cap | 0.52B |
| Dividend yield | 0.00% |
Available research for DNA
Covered Call on DNA: how it works, illustrative setup around the real 10.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DNA: how it works, illustrative setup around the real 10.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DNA: how it works, illustrative setup around the real 10.02 USD price, max profit/loss, breakeven and when to use it. Educational.
DNA technical analysis: range, last 10.02 USD, RSI 33.1, 52w range 6.52 USD–18.22 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is DNA in?
Ginkgo Bioworks Holdings (DNA) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is DNA in an uptrend or downtrend?
As of 2026-10-26, DNA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DNA's trailing P/E ratio?
DNA's trailing P/E is -1.46, with a market cap of 0.52B. See the earnings research page for full valuation detail.